Abstract
Abiraterone and enzalutamide are in widespread clinical use because of their favorable safety and efficacy. Nonetheless, even with newer agents, resistance develops overtime. In this review, we discuss mechanisms of resistance to these newer agents as well as novel therapeutic agents. We also review the literature to help clinicians decide which agent to begin with and when to stop or switch androgen receptor agents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 340-347 |
| Number of pages | 8 |
| Journal | Urologic Oncology: Seminars and Original Investigations |
| Volume | 34 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2016 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Androgen receptor therapies
- Novel therapies
- Prostate cancer
- Resistance mechanisms
Fingerprint
Dive into the research topics of 'Utility of novel androgen receptor therapies in the real world: A nuanced approach'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS